Intensity Therapeutics (NASDAQ:INTS – Get Free Report) and Clever Leaves (NASDAQ:CLVR – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Intensity Therapeutics and Clever Leaves, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Intensity Therapeutics | 1 | 0 | 3 | 1 | 2.80 |
| Clever Leaves | 0 | 0 | 0 | 0 | 0.00 |
Intensity Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 44.03%. Given Intensity Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Intensity Therapeutics is more favorable than Clever Leaves.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Intensity Therapeutics | N/A | -116.61% | -94.01% |
| Clever Leaves | N/A | N/A | N/A |
Volatility & Risk
Intensity Therapeutics has a beta of 2.76, suggesting that its share price is 176% more volatile than the S&P 500. Comparatively, Clever Leaves has a beta of 3845.81, suggesting that its share price is 384,481% more volatile than the S&P 500.
Earnings & Valuation
This table compares Intensity Therapeutics and Clever Leaves”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Intensity Therapeutics | N/A | N/A | -$11.61 million | ($3.57) | -1.36 |
| Clever Leaves | $17.42 million | 0.00 | -$17.90 million | ($9.66) | -0.00 |
Intensity Therapeutics has higher earnings, but lower revenue than Clever Leaves. Intensity Therapeutics is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
3.7% of Intensity Therapeutics shares are owned by institutional investors. Comparatively, 6.9% of Clever Leaves shares are owned by institutional investors. 7.6% of Intensity Therapeutics shares are owned by company insiders. Comparatively, 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Clever Leaves beats Intensity Therapeutics on 7 of the 13 factors compared between the two stocks.
About Intensity Therapeutics
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
About Clever Leaves
Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.
Receive News & Ratings for Intensity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intensity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
